Lascco
Company Team Projects Media Contact
Management
Clinical Advisory Board


MANAGEMENT

Samareh Lajaunias

Samareh Lajaunias Azeredo da Silveira - Managing Director
Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Since then, she managed the development of projects in the field of infectious diseases (at Sepstone Diagnostics, a spin-off of LASCCO), gene therapy, and neuroinflammatory disorders. Samareh holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL) – laboratory of Prof. Patrick Aebischer. Her work led to the publication of several articles in peer-reviewed journals.

Frederic Lajaunias

Frédéric Lajaunias - Managing Director
Frédéric has 9 year experience in early stage development. In 2007, he co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Prior to founding LASCCO, Frédéric served at Abbott Laboratories as manager for the Swiss virology division. Before that, he carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders.Frédéric holds a PhD in biology (immunology), from the University of Paris VII, andan MBA with a specialization in Entrepreneurship from the University of Geneva.

Toni Perez

Toni Perez - Chief Medical Officer
Toni is a MD, specialist in Intensive Care, with diplomas of Pharmaceutical Industry and General Management Program. Prior to joining Combioxin, Toni was Head of Clinical Research of Infectious Diseases at Novartis, Head of Clinical Development of Anti-Infectives at Basilea Pharmaceutica, Area Head of Clinical Research in Oncology at Almirall, Medical Director of Gastro-intestinal track and CNS and a board member at Esteve. He is a consultant to several pharma companies. During is career, Toni has contributed to the development, registration and marketing of medicines in infectious diseases, oncology, CNS, and gastro-intestinal and urinary tracts among others.

Shelly Bustion

Shelly Bustion - Head of Clinical Operations
Shelly is a multinational expert in clinical trial/program and line manager with over 19 years of experience in the pharmaceutical and medical device industries. She has conducted several clinical trials in all development phases and in many therapeutic areas. Shelly has managed team members at strategic program and clinical trial levels. She has in-depth knowledge of the various clinical development areas and has brought 6 products to the market. Shelly is also a lecturer and trainer at the University of Geneva.

Kristen Peterson

Kristen Peterson - Pharmaceutical Development and CMC
Kristen is a pharmaceuticals expert with over 20 years of experience in process and product development of liposomes. She has directed the process development, scale-up and technology transfer of numerous products from early clinical development through commercialization. Kristen held director-level positions in liposomal process development and manufacturing at ALZA. She also held various Engineering positions with Sequus Pharmaceuticals where she was instrumental in the Doxil® manufacturing process development. Prior to Sequus, she worked at Syntex on other sterile controlled release dosage forms. Kristen received her B.S. in Chemical Engineering from the University of California, Berkeley.

Peter Working

Hedvika Lazar - Clinical Affairs
In 2002, Hedvika joined Berna Biotech as a Clinical Development and Medical Affairs Manager, where she was responsible for influenza vaccines clinical activities. Hedvika then joined the monoclonal antibodies projects at Berna Biotech and then at Kenta Biotech, a spin-off of Berna Biotech, as Head of Clinical Development. She was also involved in pre-clinical programs and took over temporarily regulatory functions. When Aridis Pharmaceuticals acquired Kenta, Hedvika was asked to reactivate the clinical trial in severe pneumonia, which had been initiated at Kenta . In 2012, Hedvika joined GlycoVaxyn as Senior Clinical Manager, responsible of the main clinical program in collaboration with J&J.

Peter Working

Peter Working - Safety and Toxicology
Peter is Board-certified in General Toxicology by the American Board of Toxicology and a Fellow of the American Academy of Toxicology. Much of his career has focused on translational research with an emphasis on oncology and antibiotics. Peter was senior toxicologist at Genentech, VP of R&D at Sequus Pharmaceuticals, VP of Analytical and Nonclinical Sciences at ALZA, and Senior VP of R&D at Cell Genesys. Peter is currently a Principal at WorkingAdvisors, LLC, specializing in early drug development. Peter has served on various industry and US governmental boards, including the Board of Scientific Counselors of the National Toxicology Program and the Board of Directors of the American Board of Toxicology.

Steve Pinder

Karen MacLeod - Regulatory
Karen is a regulatory and drug development expert specializing in early product development, chemistry, manufacturing and controls (CMC), and early clinical development. She has over 25 years of experience in the pharmaceutical field, much of this involving development and regulatory approval of liposome formulations. She started her career at Liposome Technology, Inc. (which later became Sequus Pharmaceuticals), where she was a member of the formulations team. Later, she directed manufacturing at CytImmune Sciences, strengthened her regulatory and clinical operations experience at the CRO, CCS Associates, and directed regulatory and US clinical operations for Marval Pharma.
Lascco